Q-omics provides the consensus-scored CRYZL2P-SEC16B profile across patient tissues and cancer cell-line models. CRYZL2P-SEC16B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CRYZL2P-SEC16B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CRYZL2P-SEC16B RNA expression shows 19,159 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, KIRC, and THYM as cancer lineages where CRYZL2P-SEC16B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYZL2P-SEC16B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYZL2P-SEC16B survival associations across molecular data types. CRYZL2P-SEC16B RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYZL2P-SEC16B RNA expression–survival associations across cancer types. High CRYZL2P-SEC16B expression shows unfavorable associations in LGG, UVM and THCA, but favorable associations in HNSC, KIRC and KIRP. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CRYZL2P-SEC16B RNA expression.
This table summarizes CRYZL2P-SEC16B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CRYZL2P-SEC16B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYZL2P-SEC16B shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRC, HNSC, STAD and COAD. The KIRC box plot shows higher CRYZL2P-SEC16B RNA expression in tumor versus normal tissue (log2 FC = +0.484, t-test p < 0.001).
This table shows molecular features associated with CRYZL2P-SEC16B in patient tissues and cancer cell lines. In patient samples, CRYZL2P-SEC16B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
